Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 57 min 39 sec ago

BRCA Patent Owners and Gene by Gene, Ltd. Resolve Patent Suit

Fri, 02/07/2014 - 12:59
HOUSTON and SALT LAKE CITY, Feb. 7, 2014 -- (Healthcare Sales & Marketing Network) -- Gene by Gene, Ltd. and Myriad Genetics, Inc., the University of Utah Research Foundation, HSC Research and Development Limited Partnership, Endorecherche, Inc., and the T...
Diagnostics, Oncology, Litigation
Myriad Genetics, Gene by Gene, BRCA testing, BRCA1, BRCA2

Ipsen announces positive top line results from phase III clinical study of Decapeptyl(R) (triptorelin pamoate) 11.25 mg administered subcutaneously in patients with prostate cancer

Fri, 02/07/2014 - 12:51
Efficacy and safety results from phase III study of triptorelin pamoate 11.25 mg administered subcutaneously are both clinically and statistically significant These results are consistent with the known efficacy and safety profile of Decapeptyl® whe...
Biopharmaceuticals, Oncology
Ipsen, Decapeptyl, triptorelin pamoate, prostate cancer

Medtronic Introduces New Generation Enlite Sensor for People with Diabetes Across Western Europe

Thu, 02/06/2014 - 17:09
Latest Continuous Glucose Monitoring Sensor Provides Improved Comfort and Sensing Experience VIENNA -- February 6, 2014 -- (Healthcare Sales & Marketing Network) -- Medtronic, Inc. (NYSE:MDT) today announced the European launch of new generation Enlite...
Devices, Monitoring, Endocrinology, Product Launch
Medtronic, Enlite glucose sensor, glucose monitor, diabetes

Ultragenyx Appoints Clay Siegall, Ph.D. and Matthew Fust to Board of Directors

Thu, 02/06/2014 - 15:43
NOVATO, Calif., Feb. 6, 2014 -- (Healthcare Sales & Marketing Network) -- Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the appointment of C...
Biopharmaceuticals, Personnel
Ultragenyx

Pathway Genomics Names Ardy Arianpour as Chief Strategy Officer

Thu, 02/06/2014 - 13:14
SAN DIEGO--(Healthcare Sales & Marketing Network)--Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services worldwide, today announced it has appointed Ardy Arianpour, MBA, as chief st...
Diagnostics, Personalized Medicine, Personnel
Pathway Genomics

Covidien Receives U.S. FDA 510(k) Clearance for Reinforced Stapling Reload Technology

Thu, 02/06/2014 - 13:08
Endo GIA™ Reinforced Reload with Tri-Staple™ technology integrates tissue reinforcement buttressing capability with surgical stapling device DUBLIN, Ireland--(Healthcare Sales & Marketing Network)--Covidien plc. (COV) announced that the U.S. Food and Dr...
Devices, Surgery, FDA
Covidien, Endo GIA, Reinforced Reload, Tri-Staple, surgical stapler

St. Jude Medical Announces First US Patient Implant of Non-Surgical, Leadless Cardiac Pacemaker

Thu, 02/06/2014 - 13:01
Commencement of LEADLESS II clinical research trial represents important milestone in bringing transformational pacing technology to U.S. patients ST. PAUL, Minn.--(Healthcare Sales & Marketing Network)--St. Jude Medical, Inc. (STJ), a global medical de...
Devices, Cardiology
St. Jude Medical, Nanostim, leadless pacemaker, LEADLESS II

Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Independence Blue Cross

Thu, 02/06/2014 - 12:51
Positive Coverage Decision Adds 2.2 Million Covered Lives for Up to Two Years of Treatment with Urgent PC MINNEAPOLIS, Feb. 6, 2014 -- (Healthcare Sales & Marketing Network) -- Uroplasty, Inc. (UPI) a medical device company that develops, manufactures ...
Devices, Urology, Reimbursement
Uroplasty, Percutaneous Tibial Nerve Stimulation, Urgent PC, overactive bladder

Spectrum Pharmaceuticals Announces FDA’s Acceptance of NDA Filing for Beleodaq(TM) (belinostat) for Injection, a novel pan-HDAC inhibitor

Thu, 02/06/2014 - 12:47
FDA grants Priority Review Designation FDA decision date based on PDUFA set for August 9, 2014 HENDERSON, Nev.--(Healthcare Sales & Marketing Network)--Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug...
Biopharmaceuticals, Oncology, FDA
Spectrum Pharmaceuticals, Beleodaq, belinostat, T-cell lymphoma

Ambrx Appoints Barry Greene to Board of Directors

Wed, 02/05/2014 - 15:25
SAN DIEGO, Feb. 5, 2014 -- (Healthcare Sales & Marketing Network) -- Ambrx Inc. today announced the appointment of Barry Greene to its board of directors. Mr. Greene has more than 20 years of experience in the healthcare, pharmaceutical and biotechnology ...
Biopharmaceuticals, Personnel
Ambrx

Boston Scientific Launches OffRoad(TM) Re-Entry Catheter System

Wed, 02/05/2014 - 13:56
System Provides Physicians New Option for Treating Complete Blockages in the Major Arteries of the Leg NATICK, Mass., Feb. 5, 2014 -- (Healthcare Sales & Marketing Network) -- Boston Scientific (BSX) has announced the U.S. launch and first use of the O...
Devices, Interventional, Product Launch
Boston Scientific, OffRoad, Re-Entry Catheter, chronic total occlusions

aTyr Pharma Appoints Frederic Chereau as President and Chief Operating Officer

Wed, 02/05/2014 - 13:42
Strategic Business Leader Brings Complementary Product Commercialization and Rare Disease Expertise SAN DIEGO, Feb. 5, 2014 -- (Healthcare Sales & Marketing Network) -- aTyr Pharma ("aTyr"), an innovative biotherapeutics enterprise, announced...
Biopharmaceuticals, Personnel
aTyr Pharma, Physiocrines

Tiltan Pharma Raises $1.5 Million

Wed, 02/05/2014 - 13:38
The capital is intended for the completion of the ongoing Phase 2 clinical trial of TL-118, for the treatment of metastatic pancreatic cancer JERUSALEM--(Healthcare Sales & Marketing Network)--Tiltan Pharma Ltd. today announced that it has raised $1.5 m...
Biopharmaceuticals, Oncology, Venture Capital
Tiltan Pharma, TL-118, pancreatic cancer, anti-angiogenic therapy

Pernix Attracts $65 Million Institutional Investment; Appoints Doug Drysdale as CEO; Settles Pending Legal Liabilities

Wed, 02/05/2014 - 13:32
HOUSTON--(Healthcare Sales & Marketing Network)--Pernix Therapeutics Holdings, Inc. (NASDAQ GM: PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced that it has hired industry veteran Doug Drysdale as Chief Executive Office...
Biopharmaceuticals, Personnel, Litigation
Pernix Therapeutics Holdings, CEDAX, NATROBA, ZUTRIPRO, OMECLAMOX-PAK

Ichor Enters into an Agreement with Pfizer to Develop Electroporation Devices for Use in Therapeutic Cancer Vaccine Regimens

Wed, 02/05/2014 - 13:25
Ichor enters into an agreement with Pfizer to develop next generation TriGrid electroporation devices for use in Pfizer's vaccine-based immunotherapies for cancer indications SAN DIEGO--(Healthcare Sales & Marketing Network)--Ichor Medical Systems, Inc....
Biopharmaceuticals, Drug Delivery, Oncology, Licensing
Ichor Medical Systems, Pfizer, TriGrid, electroporation

Questcor Pharmaceuticals Expands Senior Management Team

Wed, 02/05/2014 - 13:21
ANAHEIM, Calif., Feb. 5, 2014 -- (Healthcare Sales & Marketing Network) -- Questcor Pharmaceuticals, Inc. (QCOR) today announced the appointment of Rajesh (Raj) Asarpota as the Company's new Chief Financial Officer, effective February 17, 2014. Michael H...
Biopharmaceuticals, Personnel
Questcor Pharmaceuticals

Reverse Medical(R) Corporation Announces New Patent for the Micro Vascular Plug (MVP(R))

Wed, 02/05/2014 - 12:59
IRVINE, Calif.--(Healthcare Sales & Marketing Network)--Reverse Medical Corporation announced today that the United States Patent Office has notified the Company that a new patent has issued entitled “Embolic Implant and Method of Use”. This new patent all...
Devices, Interventional
Reverse Medical, Micro Vascular Plug, vascular embolization

Pluristem Strengthens Executive Team; Announces Senior Executive Appointments

Wed, 02/05/2014 - 12:53
HAIFA, Israel, Feb. 5, 2014 -- (Healthcare Sales & Marketing Network) -- Pluristem Therapeutics, Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced the appointments of two of its senior executives. These executiv...
Regenerative Medicine, Personnel
Pluristem Therapeutics, cell therapy, PLX cells

Ipsen announces clinical results of Dysport(R) Next Generation (DNG) and its intent to file the first ready-to-use liquid toxin A in Europe and ROW(1)

Wed, 02/05/2014 - 12:46
DNG efficacious at single and repeated dose In cervical dystonia Phase III study, DNG significantly superior to placebo. Non-inferiority versus Dysport® at week 4 not demonstrated In glabellar lines Phase II study, DNG superior to placebo and com...
Biopharmaceuticals
Ipsen, Dysport, cervical dystonia, glabellar lines, toxin A

BOTOX(R) (Botulinum toxin type A) Receives Approval in the UK for the Treatment of Ankle Disability due to Lower Limb Spasticity Associated with Stroke in Adults

Tue, 02/04/2014 - 16:00
BOTOX® becomes the first and only neuromodulator to be approved specifically for the treatment of both upper and lower limb spasticity in adults who have had a stroke MARLOW, England, February 4, 2014 -- (Healthcare Sales & Marketing Network) --Tod...
Biopharmaceuticals, Neurology, Regulatory
Allergan, BOTOX, Botulinum toxin, lower limb spasticity, stroke

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong